Pioglitazone randomised Italian study on metabolic syndrome (PRISMA): Effect of pioglitazone withmetformin on HDL-C levels in type 2 diabetic patients

Journal of Endocrinological Investigation

Volumn 36, Issue 8, 2013, Pages 606-616

  Genovese, S ^a   Passaro, A ^b   Brunetti, P ^c   Comaschi, M ^d   Cucinotta, D ^e   Egan, C G ^f   Chinea, B ^g   Bravi, F ^g   Di Pietro, C ^h  

^a IRCCS MULTIMEDICA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d Centro per la Cura Del Piede Diabetico ICLAS di Rapallo   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f Primula Multimedia SRL   (Italy)

^g Department of Biometrics   (Italy)

^h Engineering   (Italy)

Author keywords

HDL cholesterol; Metabolic syndrome; Pioglitazone; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE; PLACEBO;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATALITY; FEMALE; FLATULENCE; FRACTURE; GASTROINTESTINAL PAIN; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; MODELS, BIOLOGICAL; PLACEBOS; THIAZOLIDINEDIONES;

EID: 84885667434     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8895     Document Type: Article

References (32)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27: 1047-53.
2. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23: 469-80.
3. Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004, 27: 2676-81.
4. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002, 287: 360-72.
5. Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diab Obes Metab 2005, 7: 675-91.
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352: 854-65.
7. Lebovitz HE, Banerji MA. Insulin resistance and its treatment with thiazolidinediones. Rec Prog Horm Res 2001, 56: 265-94.
8. Campbell IW. Pioglitazone - an oral antidiabetic agent and metabolic syndrome modulator. Can theory translate into practice? Br J Diabetes Vasc Dis 2005, 5: 209-16.
9. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006, 55: 517-22.
10. DeFronzo RA, Tripathy D, Schwenke DC, et al. ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011, 364: 1104-15.
11. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003, 25: 1074-95.
12. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004, 89: 6068-76.
13. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A; PROactive Study Group. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004, 27: 1647-53.
14. Goldberg RB, Kendall DM, Deeg MA, et al; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28: 1547-54.
15. Berhanu P, Kipnes MS, Khan MA, et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res 2006, 3: 39-44.
16. Derosa G, D'Angelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006, 31: 375-83.
17. Deeg MA, Buse JB, Goldberg RB, et al. GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007, 30: 2458-64.
18. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366: 1279-89.
19. Barter P, McPherson YR, Song K, et al. Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. J Clin Endocrinol Metab 2007, 92: 2041-5.
20. Chirovsky DR, Fedirko V, Cui Y, Sazonov V, Barter P. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. Eur J Cardiovasc Prev Rehabil 2009, 16: 404-23.
21. Ferrannini E, Betteridge DJ, Dormandy JA, et al. High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive. Diabetes Obes Metab 2011, 13: 759-64.
22. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
23. Jeppsson JO, Kobold U, Barr J, et al. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002, 40: 78-89.
24. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970, 11: 583-95.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18: 499-502.
26. Hoefner DM, Hodel SD, O'Brien JF, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 2001, 47: 266-74.
27. Wiedmann S, Fischer M, Koehler M, et al. Genetic variants within the LPIN1 gene, encoding lipin, are influencing phenotypes of the metabolic syndrome in humans. Diabetes 2008, 57: 209-17.
28. Perez A, Khan M, Johnson T, Karunaratne M. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res 2004, 1: 44-50.
29. Wang CH, Ting MK, Verma S, et al. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J 2006, 152: 1051.e1-8.
30. Werner C, Kamani CH, Gensch C, Böhm M, Laufs U. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 2007, 56: 2609-15.
31. Jones PH. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus. Am J Cardiol 2007, 99: 133B-40B.
32. Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol 2009, 32: 482-6.